Christian Behrenbruch
CIK: 0002037713
Transaction Breakdown
Open Market Buys (P)2 (100.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
TLX
Telix Pharmaceuticals Ltd
DirectorOfficer
Discretionary Trading P&L
Holdings
About Behrenbruch Christian
Behrenbruch Christian (SEC CIK 0002037713) files insider reports with the SEC as MD & Group CEO of Telix Pharmaceuticals Ltd (TLX).
Signal8 holds 2 ownership filings by Behrenbruch Christian (1 Form 3, 1 Form 4), filed between Mar 18, 2026 and May 6, 2026. Those filings report 2 transactions, from Apr 28, 2026 to Apr 29, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Behrenbruch Christian's filings is in NORTH MELBOURNE.
Recent filings by Behrenbruch Christian
Other insiders filing for Telix Pharmaceuticals Ltd (TLX)
- Smith Darren Charlton, Group Chief Financial Officer
- GILL DAVID N, Director
- Jellison William R, Director
- Rivas Maria, Director
- Cade David Norman, Group Chief Medical Officer
- Nelson Mark Alexander, Director